Diloxanide furoate
Phase 3
Diloxanide furoate is one of 6 therapeutic programs targeting Liver abscess. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
5 competitors in Liver Abscess
#DrugCompanyPhaseTrials
1Cipro
BayerApproved
Avelox
BayerApproved
Rocephin
CConrado Roberto Hoffmann Filho
Approved
Invanz
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Avycaz
PPhiladelphia Eye Associates
Approved
Diloxanide furoate
PPost Graduate Institute of Medical Education and Research, Chandigarh
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Liver abscess1 trial
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Diloxanide furoate. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 3[1]